{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=117",
    "query": {
      "intervention": "Combination Agent",
      "page": 117
    },
    "page_size": 10
  },
  "pagination": {
    "page": 117,
    "page_size": 10,
    "total_count": 5572,
    "total_pages": 558,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=118&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=116&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T15:37:23.520Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02799381",
      "title": "A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease (PD)"
      ],
      "interventions": [
        {
          "name": "Optimized antiparkinsonian treatment",
          "type": "DRUG"
        },
        {
          "name": "Levodopa-Carbidopa Intestinal Gel (LCIG)",
          "type": "DRUG"
        },
        {
          "name": "CADD-Legacy ambulatory infusion pump",
          "type": "DEVICE"
        },
        {
          "name": "Percutaneous endoscopic gastrostomy tube",
          "type": "DEVICE"
        },
        {
          "name": "Jejunal extension tube",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2017-02-09",
      "completion_date": "2019-09-19",
      "has_results": true,
      "last_update_posted_date": "2020-08-18",
      "last_synced_at": "2026-11-20T15:37:23.520Z",
      "location_count": 2,
      "location_summary": "Port Charlotte, Florida • Round Rock, Texas",
      "locations": [
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "Round Rock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02799381"
    },
    {
      "nct_id": "NCT03726307",
      "title": "Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Transplant",
        "Renal Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "DCreg: 0.5 million cells/kg+SOC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DCreg: 1.2 million cells/kg+SOC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DCreg:2.5 to 5.0 million cells/kg+SOC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Angus W. Thomson PhD DSc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2019-04-10",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-11-20T15:37:23.520Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03726307"
    },
    {
      "nct_id": "NCT00000236",
      "title": "Buprenorphine Pharmacology Related to Addiction Treatment - 18",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Buprenorphine/naloxone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-08-17",
      "last_synced_at": "2026-11-20T15:37:23.520Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000236"
    },
    {
      "nct_id": "NCT04869137",
      "title": "Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Merkel Cell Carcinoma",
        "Neuroendocrine Carcinoma of the Skin",
        "Trabecular Carcinoma of the Skin"
      ],
      "interventions": [
        {
          "name": "Lenvatinib Oral Product",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2021-05-28",
      "completion_date": "2026-09",
      "has_results": true,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-11-20T15:37:23.520Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04869137"
    },
    {
      "nct_id": "NCT02722967",
      "title": "Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Major Depressive Disorder",
        "Bipolar I Disorder"
      ],
      "interventions": [
        {
          "name": "Aripiprazole + IEM (Ingestible Event Marker)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 49,
      "start_date": "2016-03",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2018-05-23",
      "last_synced_at": "2026-11-20T15:37:23.520Z",
      "location_count": 4,
      "location_summary": "Granada Hills, California • Rochester, New York • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02722967"
    },
    {
      "nct_id": "NCT05162300",
      "title": "Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Photoaging",
        "Wrinkle",
        "Sun Damaged Skin"
      ],
      "interventions": [
        {
          "name": "Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Vitality Institute Medical Products",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-12-08",
      "completion_date": "2022-02-01",
      "has_results": false,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-11-20T15:37:23.520Z",
      "location_count": 1,
      "location_summary": "Rancho Mirage, California",
      "locations": [
        {
          "city": "Rancho Mirage",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05162300"
    },
    {
      "nct_id": "NCT00762320",
      "title": "Comparison of Liquid Kaletra and Low Dose Kaletra Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Low dose Kaletra tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phoenix Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Years to 18 Years"
      },
      "enrollment_count": 8,
      "start_date": "2008-10",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2014-03-24",
      "last_synced_at": "2026-11-20T15:37:23.520Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00762320"
    },
    {
      "nct_id": "NCT04848662",
      "title": "To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "BDA MDI (PT027) 160/180 μg",
          "type": "DRUG"
        },
        {
          "name": "Pulmicort Respules 0.5 MG/ML Inhalation Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bond Avillion 2 Development LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "4 Years to 8 Years"
      },
      "enrollment_count": 12,
      "start_date": "2021-05-06",
      "completion_date": "2021-07-08",
      "has_results": true,
      "last_update_posted_date": "2022-05-11",
      "last_synced_at": "2026-11-20T15:37:23.520Z",
      "location_count": 2,
      "location_summary": "Oklahoma City, Oklahoma • Boerne, Texas",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Boerne",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04848662"
    },
    {
      "nct_id": "NCT05609968",
      "title": "Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Sacituzumab Govitecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 614,
      "start_date": "2023-02-06",
      "completion_date": "2028-08-23",
      "has_results": false,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-11-20T15:37:23.520Z",
      "location_count": 16,
      "location_summary": "Mobile, Alabama • Oceanside, California • Clermont, Florida + 12 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Clermont",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05609968"
    },
    {
      "nct_id": "NCT03789097",
      "title": "Vaccination With Flt3L, Radiation, and Poly-ICLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma",
        "Metastatic Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Flt3L",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2019-04-05",
      "completion_date": "2025-09-22",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-20T15:37:23.520Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03789097"
    }
  ]
}